Skip to content
Richard L. Wahl, MD, director of Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis, spoke with The Wall Street Journal about how innovative radiopharmaceuticals and radiation treatments could offer new ways of treating metastatic disease and how biomedical companies are investing in these treatments.
Radiopharmaceuticals are still a niche form of cancer treatment; however, recent U.S. Food and Drug Administration approval of new therapies and promising data from several experimental drugs has spurred venture capital investment in new radiopharmaceutical startups.
Opens in a new window
Opens an external site
Opens an external site in a new window